UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039721
Receipt number R000045302
Scientific Title ABO blood groups as risk factor of tuberculosis: network meta-analysis.
Date of disclosure of the study information 2020/03/06
Last modified on 2021/12/07 17:45:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

ABO blood groups as risk factor of tuberculosis: network meta-analysis.

Acronym

ABO blood groups as risk factor of tuberculosis: network meta-analysis.

Scientific Title

ABO blood groups as risk factor of tuberculosis: network meta-analysis.

Scientific Title:Acronym

ABO blood groups as risk factor of tuberculosis: network meta-analysis.

Region

Japan


Condition

Condition

Tuberculosis

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Tuberculosis infection is a communicable disease caused by Mycobacterium tuberculosis, which spread from person to person through the air. Globally, an estimated 1.5 million people died out of 10 million tuberculosis (TB) cases. Well-established risk factors for TB infection includes human immunodeficiency virus infection, malnutrition, diabetes, alcohol abuse, use of immunosuppressive drugs, and exposure to tobacco smoke.
The ABO blood group was originally discovered for a safe blood transfusion in early 20th century. Each of two allele has antigen A, B, or null status. A combination of these alleles determines blood type of an individual (types A, B, AB, and O). Since its discovery, there has been an ongoing interest in the potential role of ABO blood groups in infectious disease. People with a specific blood group have an increased or decreased risk of some infectious diseases. For example, while a person with blood type O appeared to be more susceptible to norovirus infection, individuals who do not have blood type O are more susceptible to schistosomiasis. Individuals with B and AB blood group are reported less likely to be infected with H. pylori. Likewise, many researches have conducted to clarify how ABO blood groups affect the risk of tuberculosis. Nonetheless, we could not reach the conclusion because of discrepant result among studies.

Basic objectives2

Others

Basic objectives -Others

We planned this systematic review to assess the association between ABO blood group and risk of tuberculosis infection.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

An ABO blood group with the lowest odds for tuberculosis will be selected as a common comparator. Then, odds ratio will be calculated for the other three blood groups using a network meta-analysis manner.

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

We will divide Tuberculosis patients and controls into four ABO blood groups.

Key exclusion criteria

Not applicable.

Target sample size



Research contact person

Name of lead principal investigator

1st name Nobuyuki
Middle name
Last name Horita

Organization

Yokohama City University

Division name

Department of Pulmonology

Zip code

236-0004

Address

3-9, Fukuura, Kanazawa, Yokohama, Japan

TEL

045-787-2800

Email

nobuyuki_horita@yahoo.co.jp


Public contact

Name of contact person

1st name Nobuyuki
Middle name
Last name Horita

Organization

Yokohama City University

Division name

Department of Pulmonology

Zip code

236-0004

Address

3-9, Fukuura, Kanazawa, Yokohama, Japan

TEL

045-787-2800

Homepage URL


Email

nobuyuki_horita@yahoo.co.jp


Sponsor or person

Institute

Yokohama City University

Institute

Department

Personal name



Funding Source

Organization

Yokohama City University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB not required

Address

IRB not required

Tel

0000000000

Email

dummy@ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 03 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2020 Year 03 Month 05 Day

Date of IRB

2020 Year 03 Month 05 Day

Anticipated trial start date

2020 Year 03 Month 05 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Study search
We will use the following search formulas.
Pubmed: ((abo [title] OR blood type [title] or blood group [title]) (tuberculosis or tb)) OR ((abo OR "blood type" or "blood group") (tuberculosis [title] or tb[title]))

Published
Int J Infect Dis. 2021 Mar;104:701-707.



Patients
We will divide Tuberculosis patients and controls into four ABO blood groups.


Analyses
The number of patients and controls will be compared between the two blood groups using the odds ratio (OR). If one or more cells in two-by-two contingency are null, 0.5 will be added to all cells.
The logarithm of OR and its standard error (SE) will be pooled using the frequentist weighted least squares approach random-model network meta-analysis using the "netmeta" command in "netmeta" package of R. A league table for OR accompanied with a 95% confidence interval (95% CI) will be presented.
A pairwise meta-analysis comparing two ABO blood groups using a group with the lowest odds for tuberculosis as a common comparator will also be conducted.


Management information

Registered date

2020 Year 03 Month 06 Day

Last modified on

2021 Year 12 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045302


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name